Asarina Pharma Proposals regarding the Board of Directors for the Annual General Meeting 2019
(April 11 2019) The following proposals (items 12-15 in the agenda) for the upcoming Annual General Meeting have been made:
Full PDFPress Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)
The shareholders of Asarina Pharma AB (publ) are hereby summoned to attend the Annual General Meeting (“AGM”) on May 8th, 2019, at 15.00 CET at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 14.30 CET and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice,…
Full PDFAsarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects
Stockholm, April 2, 2019: Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects.
Full PDFAsarina Pharma Year-End Report 2018 shows solid progress
Stockholm, 25 February, 2019: Asarina Pharma AB releases its Year-End Report including financials for the fourth quarter 2018 and for the full year 2018. (READ THE FULL YEAR-END REPORT IN PDF HERE (http://docs.wixstatic.com/ugd/641552_cd037716c08b48c69d458724079a39d2.pdf).)
Full PDFAsarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial
Stockholm – December 18, 2018. On December 17 Asarina Pharma’s Scientific Advisory Board (SAB) gave its full backing to the company’s upcoming trial of a new preventive treatment for Menstrual Migraine. The SAB comprises world-leading independent scientists in obstetrics, gynaecology, neurology and pharmacology, including Prof Anne MacGregor, one of the world’s foremost authorities on headache…
Full PDF